Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Current progress in pharmacogenetics.

Literature DB >> 21235621

Current progress in pharmacogenetics.

Abstract

The study of genetic variation has the potential to aid understanding of the mechanisms underlying the observed inter-individual variation in drug response and by which idiosyncratic adverse effects occur. In this review, we outline current progress in pharmacogenetics using examples to highlight both mechanisms of influence of polymorphisms and research strategies for their detection. In the final sections we discuss contemporary challenges for both researchers and clinicians.

Mesh：

Substances：

Year: 2011 PMID： 21235621 PMCID： PMC3099369 DOI： 10.1111/j.1365-2125.2011.03912.x

Source DB: PubMed Journal: Br J Clin Pharmacol ISSN： 0306-5251 Impact factor: 4.335

43 in total

1. Both populations and individuals are evolutionary targets: pharmacogenomic and cultural indicators.

Authors: W Kalow
Journal: Pharmacogenomics J Date: 2002 Impact factor: 3.550

Review 2. Direct-to-consumer genome testing: opportunities for pharmacogenomics research?

Authors: Barbara Prainsack; Howard Wolinsky
Journal: Pharmacogenomics Date: 2010-05 Impact factor: 2.533

3. The path to personalized medicine.

Authors: Margaret A Hamburg; Francis S Collins
Journal: N Engl J Med Date: 2010-06-15 Impact factor: 91.245

4. A global view of epistasis.

Authors: Jason H Moore
Journal: Nat Genet Date: 2005-01 Impact factor: 38.330

5. The need for education in pharmacogenomics: a regulatory perspective.

Authors: F W Frueh; F Goodsaid; A Rudman; S-M Huang; L J Lesko
Journal: Pharmacogenomics J Date: 2005 Impact factor: 3.550

6. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.

Authors: Ronald Dahl; Kian Fan Chung; Roland Buhl; Helgo Magnussen; Vladimir Nonikov; Damon Jack; Patricia Bleasdale; Roger Owen; Mark Higgins; Benjamin Kramer
Journal: Thorax Date: 2010-06 Impact factor: 9.139

Review 7. Diabetes and hypoglycaemia in young children and mutations in the Kir6.2 subunit of the potassium channel: therapeutic consequences.

Authors: I Flechtner; P de Lonlay; M Polak
Journal: Diabetes Metab Date: 2006-12 Impact factor: 6.041

8. The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer.

Authors: L A Lammers; R H J Mathijssen; T van Gelder; M J Bijl; A-J M de Graan; C Seynaeve; M A van Fessem; E M Berns; A G Vulto; R H N van Schaik
Journal: Br J Cancer Date: 2010-08-10 Impact factor: 7.640

Review 9. Venous thrombosis: a multicausal disease.

Authors: F R Rosendaal
Journal: Lancet Date: 1999-04-03 Impact factor: 79.321

Review 10. Adjuvant targeted therapy in early breast cancer.

Authors: John Mackey; Deanna McLeod; Joseph Ragaz; Karen Gelmon; Sunil Verma; Kathleen Pritchard; Kara Laing; Louise Provencher; Lauren F Charbonneau
Journal: Cancer Date: 2009-03-15 Impact factor: 6.860

4 in total

1. Polymorphisms in genes involved in drug detoxification and clinical outcomes of anthracycline-based neoadjuvant chemotherapy in Chinese Han breast cancer patients.

Authors: Minghua Ji; Jinhai Tang; Jianhua Zhao; Bin Xu; Jianwei Qin; Jianwei Lu
Journal: Cancer Biol Ther Date: 2012-03-01 Impact factor: 4.742